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Abstract
Background: The binding of EGFR and its ligands leads to autophosphorylation of receptor tyrosine kinase as well
as subsequent activation of signal transduction pathways that are involved in regulating cellular proliferation,
differentiation, and survival. An EGFR inhibitor, cetuximab binds to EGFR and consequently blocks a variety of
cellular processes. KRAS/BRAF mutations are known to be associated with a low response rate to cetuximab. In the
present study, to clarify the anti-tumor mechanisms of cetuximab, we evaluated the KRAS/BRAF status,
phosphorylation level of the EGFR pathway, and the tumor suppression effect in vivo, using a human colon cancer
cell line HT29, which exhibited the highest EGFR expression in response to the cetuximab therapy among the 6
colorectal cancer cell lines tested.
Findings: The conventional growth suppression assay did not work efficiently with cetuximab. EGF, TGF-a, and IGF
activated the EGFR/MAPK cell signaling pathway by initiating the phosphorylation of EGFR. Cetuximab partially
inhibited the EGFR/MAPK pathway induced by EGF, TGF-a, and IGF. However, cetuximab exposure induced the
EGFR, MEK, and ERK1/2 phosphorylation by itself. Mouse xenograft tumor growth was significantly inhibited by
cetuximab and both cetuximab-treated and -untreated xenograft specimens exhibited phosphorylations of the
EGFR pathway proteins.
Conclusions: We have confirmed that cetuximab inhibited the EGFR/MAPK pathway and reduced tumor growth in
the xenografts while the remaining tumor showed EGFR pathway activation. These results suggest that: ( i ) The
effect of cetuximab in growth signaling is not sufficient to induce complete growth suppression in vitro; ( ii ) time-
course monitoring may be necessary to evaluate the effect of cetuximab because EGFR signaling is transmitted in
a minute order; and ( iii ) cetuximab treatment may have cells acquired resistant selectively survived in the
heterogeneous cancer population.
Background
The epidermal growth factor receptor (EGFR) is a trans-
membrane glycoprotein that constitutes one of four
members of the erbB family of tyrosine kinase receptors
[1]. EGFR regulates the key processes of cell biology,
including proliferation, survival, and differentiation dur-
ing development and tissue homeostasis [2]. One of the
most common approaches to inhibit EGFR signaling in
the anticancer therapeutic context has been to develop
monoclonal antibodies against EGFR. The monoclonal
antibody 225 (i.e. cetuximab) is one of several antibodies
raised by inoculation of mice with A431 epidermoid car-
cinoma cells [3] and it was subsequently selected to gen-
erate a human mouse chimeric molecule for clinical
development [4]. Cetuximab (marketed under the name
Erbitux) is a chimeric (mouse/human) monoclonal anti-
body that inhibits the epidermal growth factor receptor
(EGFR) [3]. It has been given by intravenous infusion to
treat metastatic colorectal cancer and head and neck
cancer [5].
It has been reported that cetuximab increases survival
in patients with advanced CRC when administered in
combination with irinotecan and fluorouracil [6]. Results
from other clinical trials have also indicated that the
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motherapy seems to be restricted to patients with the
wild-type KRAS gene; with the best outcomes being
observed in those with unmutated forms of both the
KRAS and BRAF genes [6-8]. A detailed understanding
of the mechanisms controlling cetuximab antitumor
activity is necessary to optimize its therapeutic efficacy
and to identify those patients who are likely to benefit
from the treatment. Although KRAS and BRAF gene
status has been considered as a meaningful biomarker,
EGFR signaling can also be regulated by several ligands,
receptors and cross-talk with other pathways. Hence,
these gene mutations may contribute to individual
tumors in varying degrees. Moreover, EGFR signaling
could change in minutes order so it is crucial to moni-
tor the dynamics of signal transduction to understand
the intrinsic biological entity of tumor growth, in addi-
tion to the representative gene mutation status. To
understand such signaling kinetics and tumor growth
suppression in response to cetuximab administration,
we used a colorectal cancer cell line, HT29, which
expressed the highest EGFR level of 6 colorectal cancer
cell lines tested. Here, we report the signaling alteration
of the EGFR/MAPK pathway initiated by three types of
growth factors in the presence/absence of cetuximab in
vitro. The protein phosphorylation status of the xeno-
graft tumor treated with cetuximab will also be
discussed.
Material and methods
Colon cancer cell lines
Six human colorectal cancer (CRC) cell lines were used
for molecular characterization. HT29 was obtained from
the American Type Culture Collection. HCT116 was
obtained from the U.S. National Cancer Institute and
CW2, JHSK-rec, JHCOLO-YI, and TT1TKB were
obtained from the RIKEN Cell Bank. HT29, CW2, and
HCT116 were grown in RPMI 1640 supplemented with
10% fetal bovine serum. JHCOLO-YI and JHSK-rec
were grown in DMEM/F12 with 10% FBS and 0.1mM
non-essential amino acid and TT1TKB was grown in
DMEM with 10% FBS. All cell lines were incubated at
37°C with 5% CO2.
Reagents
The following 3 growth factors were used for growth
signal stimulation: Epidermal Growth Factor (EGF,
SIGMA-ALDRICH), Transforming Growth Factor-a
(TGF-a, Pepro Tech House), and Insulin-like growth
factor-I human (IGF, SIGMA-ALDRICH). Each growth
factor was dissolved in the medium at the following
concentrations: EGF, 100ng/ml; TGF-a, 50ng/ml; and
IGF, 50ng/ml. Fluorouracil (5-FU, Kyowa Hakko Kirin),
an anti-human EGFR monoclonal antibody, cetuximab
(Erbitax, Bristol-Myers K.K.) were used in a serial dilu-
tion for growth suppression assays in vitro. When cetux-
imab was injected into nude mice (described details
below), the dose was 10mg/kg.
DNA sequencing
Human KRAS exon 2 (codon 12, 13) and BRAF sequen-
cing were performed with genomic DNA subjected to
PCR amplification with the following set of intronic pri-
mers: KRAS forward 5’-GGCCTGCTGAAAAT-
GACTGA-3’,r e v e r s e5 ’-GTCCTGCACCAGTAATA
TGC-3’ [9]; and BRAF exon 15 (codons 582-620) for-
ward 5’-TGTTTTCCTTTACTTACTACACCTCA-3’,
reverse 5’-TCAGTGGAAAAATAGCCTCAA-3’ [10].
The PCR products were then sequenced using the Big
Dye Terminator V3.1 (Applied Biosystems) according to
the protocol supplied by the manufacturer.
Growth suppression assay
Cells (5,000 for cell/swell) were seeded on to a 96-well
plate in an appropriate medium with FBS. Forty-eight
hours later, the cells were treated with cetuximab with a
10-fold series of concentrations, and incubated for
another 48 hours. Water-soluble tetrazolium salts were
added to each well and incubated for 3-6 hours at 37°C
(CCK-8, Dojindo). Absorbance was measured at 450
nm, with a reference filter at 520-540 nm, using a
microplate reader.
Western blot
Cells were seeded in a T-25 cell culture flask in
RPMI1640 containing 10% FBS. After the cells reached
80% confluence, the medium was replaced with serum-
free RPMI for 24 hours. Effects by serum starvation,
such as induction of apoptosis, have been reported for
various types of cells including gliomas, bladder and
colon carcinomas [11-14]. There are several reports
describing the effects of serum starvation in HT29 cells
for 24 hours [15,16] and this procedure has been well
accepted as a way of seeing the effect of cell growth sig-
naling in general [17]. In the present study, we decided
to set a 24 hours serum starvation sample as the control
for the following EGFR signaling study. After the serum
starvation was completed, the cells were stimulated with
combinations of EGF 100ng/ml, TGF-a 50ng/ml, and
IGF 50ng/ml, and incubated with cetuximab 300 μg/ml,
resulting in a total of 7 conditions for 0, 1, 5, 10, 15
minutes. The cells were then washed with PBS and
lysed with Pink Buffer containing 9 M urea (Sigma), 4%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesul-
fonate (CHAPS; Calbiochem), 2% pH 8.0-10.5 Pharma-
lyte (Amersham Pharmacia Biotech, Piscataway, NJ), and
65 mM DTT (Amersham Pharmacia Biotech) [18]. The
full fraction of protein was resolved using NuPAGE
® 4-
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tions and transferred to a nitrocellulose membrane. The
resulting membranes were blocked with 5% nonfat dried
milk (cell signaling technology) in 0.1% Tween 20 (Bio-
Rad) in PBS for 1 hour. Membranes were then incu-
bated with primary antibodies; the dilution factors were
all 1:1000 EGFR and p-EGFR(Tyr1045) (Cell Signaling
Technology), p-MEK(ser218/ser222) (ECM Biosciences),
p-ERK(Thr-202/Tyr-204) and pan-Actin (Thermo),
overnight at 4°C. Next, the membranes were washed 3
times for 5 minutes in 0.1% Tween 20 in PBS, incubated
with an HRP-conjugated secondary antibody for 1 hour
at 4°C, and washed 3 times for 5 minutes in 0.1%
Tween 20 in PBS. Chemiluminescence detection
reagents (Thermo) were incubated with the membranes
for 10 minutes, which was followed by film develop-
ment. The signal intensities of phosphorylated EGFR,
MEK, and ERK protein levels are expressed in an arbi-
trary unit (AU).
Xenograft model
HT29 cells (1.0 × 10
7) were injected subcutaneously into
the right and left side of the back of 5 week old female
athymic nude mice (CLEA japan: Central laboratory for
experimental animals Japan). Tumor volume was calcu-
lated every 2-3 days with a caliper and using the follow-
ing formula: Volume = length × width × height. After
the tumors reached approximately 100mm
3,e i t h e r4 0μl
of saline solution or 40 μl of cetuximab solution (5mg/
ml) was intravenously administered to each mouse twice
a week. Animals care was in accordance with our insti-
tution’s guidelines. All animal experiments in this study
were approved by the Iwate Medical University Ethical
Committee for Animal Experiment Regulation, 22-007,
Morioka, Japan.
Immunohistochemistry
After euthanization of the mice, the tumors were
excised and preserved in 10% formalin. Hematoxylin
and eosin (HE) staining was performed using a standard
technique. Immunohistochemical (IHC) staining proce-
dures for total EGFR were as follows: Paraffin was
depleted from a slide and incubated with pepsin solu-
tion for 20 min at 37°C. Tissue sections were covered
with 3% H2O2 to block endogenous peroxidase for 10
min at RT (room temperature). Slides were incubated
with anti-EGFR at 1:50 (NICHIREI Bioscience) for
60min at RT. After washing TBS (Tris-Buffered saline),
the slides were incubated with a secondary antibody
(EnVision™: DAKO JAPAN) for 30 min at RT. Tissue
staining was visualized using a DAB (3, 3’-[[diaminoben-
zidine]]) substrate chromogen solution.
IHC staining for phosphorylated proteins was con-
ducted as follows: After the same preprocessing of the
anti-EGFR antibody as described above, tissue sections
were blocked with protein block serum free to prevent
nonspecific reactions for 10 min at RT. Slides were
incubated with the primary antibody [pEGFR(1045) at
1:50, Cell Signaling Technology], [pERK (Thr202/
Tyr204) Rabbit mAb at 1:300, Cell Signaling] Technol-
o g yo v e r n i g h ta t4 ° C .T h es l i d e sw e r et h e ni n c u b a t e d
with the secondary antibody (DAKO JAPAN) for 15
min at RT. Next, the slides were incubated with tyra-
mide for 15 min. Tissue staining was visualized using a
DAB substrate chromogen solution. The slides were
then counterstained with hematoxylin, dehydrated, and
mounted.
Results
Characterization of colorectal cancer cell lines
Total EGFR protein expression was detected in HT29,
JHCOLO-YI, JHSK-rec, HCT116, and TT1TKB by Wes-
tern blot analysis. Three cell lines (HT29, HCT116, and
TT1TKB) exhibited a relatively high level of protein
expression, while one (JHCOLOYI) was intermediate,
and 2 (CW2 and JHSK-rec) were very weak or showed
no expression (Figure 1A). Sequencing analysis revealed
that HT29, JHCOLO-YI, and CW2 were KRAS wild-
type, whereas JHSK-rec, HCT116, and TT1TKB were
KRAS mutant-type; JHCOLO-YI, JHSK-rec, HCT116,
and TT1TKB were BRAF wild-type, whereas HT29 was
BRAF mutant-type (Figure 1B) (Table 1).
Growth suppression assay with cetuximab
To determine the effects of cetuximab on cell growth in
vitro, we performed a growth inhibitory assay with 6
CRC cell lines. A conventional chemosensitivity test
using 5-FU or cetuximab was performed to identify if a
growth inhibitory effect could be seen in a dose-depen-
dent manner. As predicted, 5-FU exhibited a growth
suppression curve with a dose-dependent manner in 4
out of 6 cell lines, whereas growth was not inhibited by
cetuximab in any of the 6 cell lines (Figure 2).
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Figure 1 Characterization of the colorectal cancer cell lines.
Protein expression of EGFR in colorectal cancer cell lines and
sequence histograms of HT29, A, Expression of EGFR in HT29, CW2,
HCT116, JHSK-rec, JHCOLO-YI and TT1TKB cells determined by
Western blot. Pan-Actin was used as a loading control. B,
Sequencing analysis of KRAS and the BRAF gene in HT29 cells.
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cetuximab
All growth factors used in the present study activated
EGFR/MAPK signaling (Figure 3) and TGF-a and IGF
induced phosphorylation of downstream signaling more
quickly than EGF did. While EGF induced sustained
phosphorylation, a cocktail of TGF-a and IGF induced
either exponential or temporal phosphorylation. We
next observed for how cetuximab alters the phosphory-
lation level and whether it induces dephosphorylation in
the presence of the above growth factors. As expected,
the level of growth factor induced phosphorelation is
decreased in the presence of cetuximab. Since all three
growth factors have an affinity for EGFR, it makes sense
that cetuximab reduces the phosphorylation levels that
they induce; however, cetuximab does not seem to inhi-
bit any of the phosphorylation levels completely. Inter-
estingly, cetuximab itself exhibited the induction of
phosphorylation in the absence of growth factors at
multiple levels of the EGFR pathway.
Inhibition of tumor growth in the mouse xenograft
Treatment with 6 injection of cetuximab for 26 days
resulted in a significant suppression of tumor growth (P
< 0.05) (Figure 4). To evaluate whether there were any
differences in the EGFR/MAPK signaling between cetux-
imab treatment (+) and (-) in vivo, we measured the
total EGFR, phosphor-EGFR, and phosphor-ERK stain-
ing in the xenograft tumor sections. There were no visi-
ble differences between cetuximab (+) and cetuximab (-)
tumors in terms of cell/tissue structure, and no necrotic
or hyperinflammatory features were found. Both EGFR
and phosphor-EGFR were stained in the cell membranes
although the degree of staining was not homogeneous
within the tumor. Phosphor-ERK nuclear staining was
seen in substantial parts of the tumors. Interestingly,
phosphor-ERK positive cells were occasionally found
next to or in the negative cells (Figure 5).
Discussion
Expression of the EGFR protein was supposed to be the
key molecule for cetuximab therapy indication. How-
ever, recent studies have indicated that EGFR IHC does
not predict the need for cetuximab treatment. Subse-
quently analysis of the KRAS mutation has been widely
accepted as giving a better prognostic value than EGFR
[7,8,19]. In fact, our examination revealed that EGFR
expression did not correlate with KRAS and BRAF
Table 1 Gene mutation status and EGFR expression of
colon cancer cell lines
Cell lines EGFR KRAS BRAF
HT29 +++ wt mt
JHCOLO-YI ++ wt wt
CW2 - wt wt
JHSK-rec ++ mt wt
HCT116 ++ mt wt
TT1TKB ++ mt wt
Wt, wild type; mt, mutant type; +++, very strong positive; ++, strong positive;
+, positive; -, negative. Level of EGFR is determined by Western blotting
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Figure 2 Growth suppression assay for in vitro antitumor
activity of cetuximab in CRC cell lines. Growth suppression
curves resulting from either 5-FU or cetuximab dose-dependent
administrations for 48h are shown. The error bar shows mean ±
SEM (standard error of the mean) of each concentration data point.
The vertical axis represents the cell viability, and the horizontal axis
represents the drug concentration.
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Figure 3 Kinetics of proteins involved in EGFR/MAPK signaling
with cetuximab in HT29 cells. A, HT29 cells were treated with
serum-free RPMI for 24 hours, followed by the addition of EGF
100ng/ml, TGF-a 50ng/ml, IGF 50ng/ml, and cetuximab 300ng/ml,
resulting in a total of 7 conditions for 0, 1, 5, 10, 15 minutes before
collections of protein lysate. The phosphorylation of EGFR, MEK, and
ERK was visualized using Western blot analysis. Actin was used as a
loading control. B, A Western blot band was plotted in an arbitrary
unit showing the time course.
Matsuo et al. BMC Research Notes 2011, 4:140
http://www.biomedcentral.com/1756-0500/4/140
Page 4 of 8status. HT29 had the KRAS wild-type with BRAF muta-
tion, and no BRAF mutations were found in other cell
lines with the mutated KRAS genotype. This is in agree-
ment with previously published observations by other
authors that mutations in KRAS and BRAF are mutually
exclusive [20,21]. We chose HT29, which has the con-
ventional criteria for cetuximab therapy (i.e. EGFR-posi-
tive and KRAS wild-type) to see how EGFR signal
transduction was altered by the signal intervention with
cetuximab.
In addition, we used a growth inhibitory assay to
examine the cytotoxicity of cetuximab to clarify if a cell-
based assay can be used in therapeutic decision making.
Surprisingly, cetuximab did not suppress cell growth in
vitro in any of the 6 cell lines, including HT29. A possi-
ble explanation for this is that antibody-class anticancer
agents including cetuximab do not seem to be as cyto-
toxic as other conventional classes of anticancer drugs,
which may require a host-dependent cytotoxic mechan-
ism (i.e., immune system) [22]. Hence, the conventional
growth suppression assay may not work efficiently with
the antibody class drugs, at least cetuximab.
HT29 is an EGFR-positive, KRAS wild-type and BRAF
mutant-type cell line. In practice, it is considered that
EGFR-positive as well as KRAS wild-type colorectal can-
cer patients have satisfied criteria for cetuximab therapy.
It has also been speculated that colorectal cancer
patients with the BRAF mutant type may be considered
to be a minor ‘non-effective’ group for cetuximab ther-
apy as determined by clinical trials [6-8]. However,
when it comes to individual patients, the grouping may
not always be fully indicative. In fact, “the effective rate
of KRAS mutant” and “non-response rate with the KRAS
wild type” are 6.7% and 64.2%, respectively [7]. Although
these rates cannot be ignored they may not be of con-
cern in practice because the gene status is currently
almost the exclusive recommended criterion. In addition
to showing the molecular mechanisms of tumor growth
suppression by cetuximab, our results provide an exam-
ple showing that it is worthwhile to consider not only
the gene status but also the signaling pathway involved
in the therapy.
All growth factors used in the present study activated
EGFR/MAPK signaling and phosphorylation of down-
stream signaling was induced more quickly by TGF-a
and IGF than EGF. This suggests that therei sac r o s s -
talk between EGFR/MAPK signaling and growth factor
induced signaling other than EGF. While EGF induced
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Figure 4 In vivo tumor suppression by cetuximab.G r o w t h
suppression of the HT29 mouse xenograft is present. HT29
xenografts were either untreated or treated with 200 μgo f
cetuximab per mouse twice a week. The tumor volume was
measured every 2-3 days, and all mice were sacrificed after 26 days
of treatment. Error bars represent the standard error of the mean.
We compared the tumor volume of treated and untreated
xenografts using the student t-test (p < 0.05).
Figure 5 Immunohistochemistry of xenograft tumors. HT29 mouse xenograft tumors were removed and stained after cetuximab treatment.
Tumor sections were stained with HE, anti-EGFR, anti-pEGFR(1045), anti-pERK(Thr202/Tyr204). Images are from cetuximab-treated (top) and
-untreated (bottom).
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Page 5 of 8sustained phosphorylation, a cocktail of TGF-a and IGF
induced either exponential or temporal phosphorylation,
suggesting that there is a negative-feedback circuit,
which regulates the level of phosphorylation at the
MEK/ERK level. Interestingly, cetuximab itself exhibited
the induction of phosphorylation in the absence of
growth factors at multiple levels of the EGFR pathway
(Figure 3). In fact, it has been reported that cetuximab
itself induced phosphorylation of EGFR at several tyro-
sine phosphorylation sites as a result of receptor dimeri-
zation and activation of the receptor tyrosine kinase
[23-25]. On the other hand, direct occlusion of the
ligand-binding site is the primary mechanism of inhibi-
tion by cetuximab [3,26]. Moreover, cetuximab-EGFR
complexes are not removed from the plasma membrane,
in contrast to the rapid receptor turnover induced by
EGF alone [23,27,28]. The ligand-EGFR complex is
rapidly internalized and then either recycled back to the
cell surface or proteolytically degraded. The internalized
EGFR interacts with various signaling proteins that are
important for sustained activation of the major signaling
pathways mediated by ERK [23,27,28]. Taken together,
the previous reports and our present results indicate
that cetuximab leads to receptor dimerization that
results in EGFR signal activation to some degree; but
the dimerization is a less substantial signal inhibitor
than the internalization of the ligand-EGFR complex
(Figure 6).
Other Investigators have hypothesized the mechanisms
of action of cetuximab as follows: (i) Inhibits internaliza-
tion of EGFR resulting in a lack of downstream phos-
phorylation [23]; (ii) Induces apoptosis by starving
growth signals [3,23]; (iii) causes an immunological
response by provoking ADCC [22]; and (iv) fills up the
EGF binding site preventing EGF from binding to its
receptor [3].
To measure the result of such mechanisms of action,
reflecting the drug’s potency, we used a widely available
method to measure cell growth using a water-soluble
tetrasolium salt, WST-8, a substrate of formazan. This
presumably reflects the number of cells in a microplate
well (i.e. CCK-8 assay). Hence, the assay system reac-
tions are maintained as long as cells generate energy
from biochemical reactions that are present such as gly-
colysis even if their growth is somewhat suppressed. In
the present study, we found no evidence for clear cetux-
imab dose-dependent growth suppression with the assay
(Figure 2) in contrast to other cytotoxic drugs such as
5-FU, which showed clear logistic growth suppression
curves. However, we found visible suppression of pro-
tein phosphorylation in the EGFR signal transduction
pathways suggesting that cetuximab affects the signal
transduction in the surviving cells that seem to be unaf-
fected at the cellular level. This may imply that it is
difficult to see the growth suppression from cetuximab
alone in the short term, for example when using a 48h
cytotoxic assay. Based on previous reports and our pre-
sent findings, it has been speculated that cetuximab may
have a minimal direct cytotoxic effect by itself although
an inhibitory effect of cetuximab on signal transduction
in protein phosphorylation can be seen. The discrepancy
between the growth suppression assay and the in vivo
growth suppression effect of cetuximab may suggest
that rapid growth suppression by cetuximab requires an
extracellular effect.
The result of histological heterogeneous staining sug-
gests that phosphorylation of the EGFR pathway compo-
nents do not occur in a synchronized manner within the
tumor. The fact that phosphor-EGFR positive cells are
present in the tumor that has responded to cetuximab,
also implies that cells which have acquired cetuximab
may have selectively survived in response to the
treatment.
Conclusions
Although KRAS gene mutation status is clinically useful
for therapeutic decision making, the molecular effect of
:EGF :Other growth factors :cetuximab
:EGFR :Other growth factor receptor
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Figure 6 Possible EGFR signaling pathways affected by
cetuximab. ➀EGF activates EGFR/MAPK signaling. ➁
Phosphorylation of downstream signaling is induced more quickly
by TGF-a and IGF than EGF. ➂Potential negative-feedback from
downstream signals. ➃Cetuximab reduces the phosphorylation level
induced by the three growth factors. ➄Cetuximab binding to the
receptor induces the receptor dimerization resulting in protein
phosphorylation of downstream proteins. However, inhibition of the
receptor internalization leads to the suppression of protein
phosphorylation in downstream proteins (as a consequence, in the
presence of cetuximab, the level of protein phosphorylation does
exist but at a very low level).
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not yet been fully elucidated. In the present study, we
assessed the effect of cetuximab in tumor growth at 3
different levels including the protein and, cell levels, and
in vivo, with gene status and EGFR expression informa-
tion. At the protein level, EGFR signaling was effectively
inhibited as a consequence of cetuximab exposure,
whereas growth suppression assay did not show a signif-
icant effect probably due to the lack of direct cytotoxi-
city. However, CRC cell line xenografts followed by
cetuximab administration to nude mice exhibited signifi-
cant growth suppression. The phosphorylation status of
the cetuximab target pathway did not visibly differ
between cetuximab-treated and -untreated tumors
removed from the mouse. These results suggest that the
antitumor effect of cetuximab cannot be predicted by
conventional growth suppression assay alone. Examina-
tion of the phosphorylation level seems to be informa-
tive, but the level does not synchronize in tumor cells
probably due to the level change occurring in minutes
order in a heterogeneous cell population. Although the
set of assays is labor intensive and time consuming, it
may compensate for the missing part in the current
decision making process for selecting cetuximab therapy,
leading to the establishment of new criteria for indivi-
dual patients.
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